Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study

Dario Cocito, Aristide Merola, Erdita Peci, Anna Mazzeo, Raffaella Fazio, Ada Francia, Paola Valentino, Rocco Liguori, Massimiliano Filosto, Gabriele Siciliano, Angelo Maurizio Clerici, Stefania Lelli, Girolama Alessandra Marfia, Giovanni Antonini, Ilaria Cecconi, Eduardo Nobile-Orazio, Leonardo Lopiano

Research output: Contribution to journalArticle

Abstract

This multi-center Italian prospective observational study reports the 4 months follow-up data of 87 patients affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) shifted from intravenous to subcutaneous immunoglobulin treatment. A therapeutic shift from intravenous to subcutaneous immunoglobulin was performed in 87 patients (66 CIDP; 21 MMN) affected by immune-mediated peripheral neuropathies with evidence of a sustained clinical response to intravenous immunoglobulin. Patients were evaluated by means of the Overall Neuropathy Limitation Scale, Medical Research Council Scale and Life Quality Index questionnaire, both at the time of therapeutic shift and after 4 months of subcutaneous immunoglobulin treatment. A sustained clinical efficacy was observed after the switch to subcutaneous immunoglobulin: the Overall Neuropathy Limitation Scale score improved in the group of 66 CIDP patients (P = 0.018), with only one subject reporting a worsening of 1 point, and remained stable in the group of 21 MMN patients (P = 0.841), with one subject reporting a worsening of two points. An improvement in the patient’s perception of therapeutic setting was reported in both groups. This large multi-center study confirms the short-term clinical equivalence of subcutaneous versus intravenous immunoglobulin and a possible improvement in the patient’s perception of therapeutic setting with the subcutaneous administration. However, further studies are required to extend the results to a longer observational period.

Original languageEnglish
Pages (from-to)2159-2164
Number of pages6
JournalJournal of Neurology
Volume261
Issue number11
DOIs
Publication statusPublished - 2014

Fingerprint

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Immunoglobulins
Intravenous Immunoglobulins
Therapeutics
Peripheral Nervous System Diseases
Observational Studies
Biomedical Research
Quality of Life
Prospective Studies

Keywords

  • Chronic inflammatory demyelinating polyneuropathy
  • Inflammatory neuropathy
  • Intravenous immunoglobulin
  • Multifocal motor neuropathy
  • Subcutaneous immunoglobulin

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Cocito, D., Merola, A., Peci, E., Mazzeo, A., Fazio, R., Francia, A., ... Lopiano, L. (2014). Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study. Journal of Neurology, 261(11), 2159-2164. https://doi.org/10.1007/s00415-014-7444-2

Subcutaneous immunoglobulin in CIDP and MMN : a short-term nationwide study. / Cocito, Dario; Merola, Aristide; Peci, Erdita; Mazzeo, Anna; Fazio, Raffaella; Francia, Ada; Valentino, Paola; Liguori, Rocco; Filosto, Massimiliano; Siciliano, Gabriele; Clerici, Angelo Maurizio; Lelli, Stefania; Marfia, Girolama Alessandra; Antonini, Giovanni; Cecconi, Ilaria; Nobile-Orazio, Eduardo; Lopiano, Leonardo.

In: Journal of Neurology, Vol. 261, No. 11, 2014, p. 2159-2164.

Research output: Contribution to journalArticle

Cocito, D, Merola, A, Peci, E, Mazzeo, A, Fazio, R, Francia, A, Valentino, P, Liguori, R, Filosto, M, Siciliano, G, Clerici, AM, Lelli, S, Marfia, GA, Antonini, G, Cecconi, I, Nobile-Orazio, E & Lopiano, L 2014, 'Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study', Journal of Neurology, vol. 261, no. 11, pp. 2159-2164. https://doi.org/10.1007/s00415-014-7444-2
Cocito, Dario ; Merola, Aristide ; Peci, Erdita ; Mazzeo, Anna ; Fazio, Raffaella ; Francia, Ada ; Valentino, Paola ; Liguori, Rocco ; Filosto, Massimiliano ; Siciliano, Gabriele ; Clerici, Angelo Maurizio ; Lelli, Stefania ; Marfia, Girolama Alessandra ; Antonini, Giovanni ; Cecconi, Ilaria ; Nobile-Orazio, Eduardo ; Lopiano, Leonardo. / Subcutaneous immunoglobulin in CIDP and MMN : a short-term nationwide study. In: Journal of Neurology. 2014 ; Vol. 261, No. 11. pp. 2159-2164.
@article{795b5ab6e82d4bc4b87a785c128387d7,
title = "Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study",
abstract = "This multi-center Italian prospective observational study reports the 4 months follow-up data of 87 patients affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) shifted from intravenous to subcutaneous immunoglobulin treatment. A therapeutic shift from intravenous to subcutaneous immunoglobulin was performed in 87 patients (66 CIDP; 21 MMN) affected by immune-mediated peripheral neuropathies with evidence of a sustained clinical response to intravenous immunoglobulin. Patients were evaluated by means of the Overall Neuropathy Limitation Scale, Medical Research Council Scale and Life Quality Index questionnaire, both at the time of therapeutic shift and after 4 months of subcutaneous immunoglobulin treatment. A sustained clinical efficacy was observed after the switch to subcutaneous immunoglobulin: the Overall Neuropathy Limitation Scale score improved in the group of 66 CIDP patients (P = 0.018), with only one subject reporting a worsening of 1 point, and remained stable in the group of 21 MMN patients (P = 0.841), with one subject reporting a worsening of two points. An improvement in the patient’s perception of therapeutic setting was reported in both groups. This large multi-center study confirms the short-term clinical equivalence of subcutaneous versus intravenous immunoglobulin and a possible improvement in the patient’s perception of therapeutic setting with the subcutaneous administration. However, further studies are required to extend the results to a longer observational period.",
keywords = "Chronic inflammatory demyelinating polyneuropathy, Inflammatory neuropathy, Intravenous immunoglobulin, Multifocal motor neuropathy, Subcutaneous immunoglobulin",
author = "Dario Cocito and Aristide Merola and Erdita Peci and Anna Mazzeo and Raffaella Fazio and Ada Francia and Paola Valentino and Rocco Liguori and Massimiliano Filosto and Gabriele Siciliano and Clerici, {Angelo Maurizio} and Stefania Lelli and Marfia, {Girolama Alessandra} and Giovanni Antonini and Ilaria Cecconi and Eduardo Nobile-Orazio and Leonardo Lopiano",
year = "2014",
doi = "10.1007/s00415-014-7444-2",
language = "English",
volume = "261",
pages = "2159--2164",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "11",

}

TY - JOUR

T1 - Subcutaneous immunoglobulin in CIDP and MMN

T2 - a short-term nationwide study

AU - Cocito, Dario

AU - Merola, Aristide

AU - Peci, Erdita

AU - Mazzeo, Anna

AU - Fazio, Raffaella

AU - Francia, Ada

AU - Valentino, Paola

AU - Liguori, Rocco

AU - Filosto, Massimiliano

AU - Siciliano, Gabriele

AU - Clerici, Angelo Maurizio

AU - Lelli, Stefania

AU - Marfia, Girolama Alessandra

AU - Antonini, Giovanni

AU - Cecconi, Ilaria

AU - Nobile-Orazio, Eduardo

AU - Lopiano, Leonardo

PY - 2014

Y1 - 2014

N2 - This multi-center Italian prospective observational study reports the 4 months follow-up data of 87 patients affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) shifted from intravenous to subcutaneous immunoglobulin treatment. A therapeutic shift from intravenous to subcutaneous immunoglobulin was performed in 87 patients (66 CIDP; 21 MMN) affected by immune-mediated peripheral neuropathies with evidence of a sustained clinical response to intravenous immunoglobulin. Patients were evaluated by means of the Overall Neuropathy Limitation Scale, Medical Research Council Scale and Life Quality Index questionnaire, both at the time of therapeutic shift and after 4 months of subcutaneous immunoglobulin treatment. A sustained clinical efficacy was observed after the switch to subcutaneous immunoglobulin: the Overall Neuropathy Limitation Scale score improved in the group of 66 CIDP patients (P = 0.018), with only one subject reporting a worsening of 1 point, and remained stable in the group of 21 MMN patients (P = 0.841), with one subject reporting a worsening of two points. An improvement in the patient’s perception of therapeutic setting was reported in both groups. This large multi-center study confirms the short-term clinical equivalence of subcutaneous versus intravenous immunoglobulin and a possible improvement in the patient’s perception of therapeutic setting with the subcutaneous administration. However, further studies are required to extend the results to a longer observational period.

AB - This multi-center Italian prospective observational study reports the 4 months follow-up data of 87 patients affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) shifted from intravenous to subcutaneous immunoglobulin treatment. A therapeutic shift from intravenous to subcutaneous immunoglobulin was performed in 87 patients (66 CIDP; 21 MMN) affected by immune-mediated peripheral neuropathies with evidence of a sustained clinical response to intravenous immunoglobulin. Patients were evaluated by means of the Overall Neuropathy Limitation Scale, Medical Research Council Scale and Life Quality Index questionnaire, both at the time of therapeutic shift and after 4 months of subcutaneous immunoglobulin treatment. A sustained clinical efficacy was observed after the switch to subcutaneous immunoglobulin: the Overall Neuropathy Limitation Scale score improved in the group of 66 CIDP patients (P = 0.018), with only one subject reporting a worsening of 1 point, and remained stable in the group of 21 MMN patients (P = 0.841), with one subject reporting a worsening of two points. An improvement in the patient’s perception of therapeutic setting was reported in both groups. This large multi-center study confirms the short-term clinical equivalence of subcutaneous versus intravenous immunoglobulin and a possible improvement in the patient’s perception of therapeutic setting with the subcutaneous administration. However, further studies are required to extend the results to a longer observational period.

KW - Chronic inflammatory demyelinating polyneuropathy

KW - Inflammatory neuropathy

KW - Intravenous immunoglobulin

KW - Multifocal motor neuropathy

KW - Subcutaneous immunoglobulin

UR - http://www.scopus.com/inward/record.url?scp=84920936663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920936663&partnerID=8YFLogxK

U2 - 10.1007/s00415-014-7444-2

DO - 10.1007/s00415-014-7444-2

M3 - Article

C2 - 25149866

AN - SCOPUS:84920936663

VL - 261

SP - 2159

EP - 2164

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 11

ER -